Risk stratification in multiple myeloma: Are we there yet?
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19416 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Meera Mohan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
The second revision of international staging system (R2‐ISS) shows promise in patients with multiple myeloma treated with a regimen of novel agent‐based induction therapy, autologous stem cell transplant and maintenance therapy, but challenges persist. This study by Alzahrani et al. underscores the importance of refining risk assessment tools for tailored treatment strategies. Commentary on: Alzahrani et al. Impact of revised international staging system 2 (R2‐ISS) risk stratification on outcomes of patients with multiple myeloma receiving autologous hematopoietic stem cell transplantation. Br J Haematol 2024;204:1944‐1952.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Myeloma Center, University of Arkansas for Medical Science, Little Rock, Arkansas, USA.
ORCID-Profile: Meera Mohan
Zitieren
APA
Mohan, M., & Schinke, C. (2024). Risk stratification in multiple myeloma: Are we there yet?. British Journal of Haematology. https://doi.org/10.1111/bjh.19416
Vancouver
Mohan M, Schinke C. Risk stratification in multiple myeloma: Are we there yet?. British Journal of Haematology. 2024. doi:10.1111/bjh.19416
BibTeX
@article{Mohan2024,
author = {Mohan, Meera and Schinke, Carolina},
title = {Risk stratification in multiple myeloma: Are we there yet?},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19416}
}
EUVIMED